Ligand Pharmaceuticals (LGND)
NASDAQ: LGND
· Real-Time Price · USD
166.75
-0.99 (-0.59%)
At close: Sep 05, 2025, 3:59 PM
166.75
0.00%
After-hours: Sep 05, 2025, 04:20 PM EDT
-0.59% (1D)
| Bid | 164.1 |
| Market Cap | 3.27B |
| Revenue (ttm) | 187.58M |
| Net Income (ttm) | -75.86M |
| EPS (ttm) | -4.06 |
| PE Ratio (ttm) | -41.07 |
| Forward PE | 22.34 |
| Analyst | Buy |
| Ask | 169.77 |
| Volume | 152,867 |
| Avg. Volume (20D) | 212,417 |
| Open | 167.86 |
| Previous Close | 167.74 |
| Day's Range | 166.07 - 169.49 |
| 52-Week Range | 93.58 - 169.49 |
| Beta | 0.84 |
About LGND
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol LGND
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for LGND stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Ligand Pharmaceuticals is scheduled to release its earnings on
Nov 6, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
6 months ago
+0.57%
Ligand Pharmaceuticals shares are trading higher a...
Unlock content with
Pro Subscription
10 months ago
+11.12%
Ligand Pharmaceuticals shares are trading higher after the company reported worse-than-expected Q3 financial results and raised its FY24 guidance.
4 weeks ago · seekingalpha.com
Ligand Pharmaceuticals Incorporated (LGND) Q2 2025 Earnings Call TranscriptLigand Pharmaceuticals Incorporated (NASDAQ:LGND ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Lauren Hay - Corporate Participant Melanie Herman - Corporate Partici...
